Compounds > citiolone
Page last updated: 2024-09-21

citiolone

Description

citiolone: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14520
CHEMBL ID2104457
CHEBI ID94403
SCHEMBL ID364495
MeSH IDM0040624

Synonyms (111)

Synonym
n-acetylhomocysteine thiolactone
2-acetamido-4-mercaptobutyric acid thiolactone
thioxidrene
n-(tetrahydro-2-oxo-3-thienyl)acetamide
nsc-22878
ahctl
citiolone
ahct
bo 714
1195-16-0
n-acetylhmocysteinethiolactone
citiolase
acetamide, n-(tetrahydro-2-oxo-3-thienyl)-
.alpha.-acetamido-.gamma.-thiobutyrolactone
nsc22878
brn 0004338
einecs 241-841-5
achtl
citiolone [inn:dcf]
alpha-acetamido-gamma-thiobutyrolactone
nsc 22878
(1)-n-(tetrahydro-2-oxothien-3-yl)acetamide
citiolona [inn-spanish]
einecs 214-793-8
n-acetylhomocysteinthiolakton [german]
n-(tetrahydro-2-oxothienyl)acetamide
citiolonum [inn-latin]
17896-21-8
PRESTWICK_1
n-acetyl-dl-homocysteine thiolactone
PRESTWICK2_000644
PRESTWICK3_000644
NCGC00179491-01
citiolone (inn)
D07105
BSPBIO_000647
BPBIO1_000713
dl-n-acetylhomocysteine thiolactone, 98%
SPBIO_002568
PRESTWICK0_000644
PRESTWICK1_000644
n-acetyl-dl-homocystein thiolactone
3-acetamidotetrahydro-2-thiophenone
2-acetamido-4-mercaptobutyric acid gamma-thiolactone
n-(2-oxothiolan-3-yl)acetamide
HMS1570A09
AKOS002808092
A804305
n,n-dimethyl-2,4-dinitro-benzenesulfonamide
HMS2097A09
n-(tetrahydro-2-oxo-3-thienyl)-acetamide
citiolonum
citiolona
n-acetylhomocysteinthiolakton
70jkl15muh ,
sitilon
5-18-11-00320 (beilstein handbook reference)
unii-70jkl15muh
n-acetyl-dl-homocystein thiolacton
mucorex
tox21_113346
nsc758402
nsc-758402
pharmakon1600-01503205
tox21_111388
dtxsid0045888 ,
dtxcid8025888
CHEMBL2104457
S4558
dl-n-acetylhomocysteine thiolactone
FT-0637623
citiolone [mi]
citiolone [inn]
citiolone [who-dd]
citiolone [mart.]
BRD-A57957888-001-01-5
AKOS016162043
CCG-213865
tox21_113346_1
NCGC00179491-04
SCHEMBL364495
n-(2-oxotetrahydrothiophen-3-yl)acetamide
2-acetamido-4-mercaptobutyric acid .gamma.-thiolactone
dl-3-(acetylamino)tetrahydro-2-thiophenone
2-acetamide-4-mercaptobutyric acid .gamma.-thiolactone
n-(2-oxotetrahydro-3-thienyl)acetamide
dl-n-acetylhomocysteinethiolactone
2-thiolanone, 3-acetamido-
2-acetamido-4-mercaptobutyric acid $g-thiolactone
HY-B0931
SR-01000872700-1
mfcd00005480
SR-01000872700-2
sr-01000872700
2-acetamido-4-mercaptobutyric acid i(3)-thiolactone
CHEBI:94403
n-(2-oxo-3-thiolanyl)acetamide
J-011416
SBI-0207034.P001
HMS3714A09
F17228
DB13442
AS-11951
Q15408416
BRD-A57957888-001-06-4
citiolase;citiolona; citiolonum; nsc 22878; nsc22878; nsc-22878
BCP30727
FT-0774860
EN300-100347
acetamide, n-(tetrahydro-2-oxo-3-thienyl)-, (a+/-)-
Z995084668

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
Cellular tumor antigen p53Homo sapiens (human)Potency18.83360.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (40.30)18.7374
1990's20 (29.85)18.2507
2000's1 (1.49)29.6817
2010's12 (17.91)24.3611
2020's7 (10.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.39%)5.53%
Reviews1 (1.39%)6.00%
Case Studies5 (6.94%)4.05%
Observational0 (0.00%)0.25%
Other65 (90.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
thiophenes[no description available]medium581mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
bromine[no description available]medium10diatomic bromine
sulfur[no description available]medium10chalcogen;
nonmetal atom		macronutrient
bromates[no description available]medium10bromine oxoanion;
monovalent inorganic anion
iodine[no description available]medium10diatomic iodinenutrient
cysteine[no description available]medium100cysteiniumfundamental metabolite
D-fructopyranose[no description available]medium70cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
bilirubin[no description available]medium10biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
homocysteine[no description available]medium10amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite
benzene[no description available]medium10aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
sulfobromophthalein[no description available]medium102-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
triiodothyronine[no description available]medium10tetrahydrothiophenes;
thiolactone		human metabolite
carbon tetrachloride[no description available]medium10chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
thioacetamide[no description available]medium10thiocarboxamidehepatotoxic agent
hydroxyproline[no description available]medium104-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
penicillamine[no description available]medium20non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
methylmercuric chloride[no description available]medium60chlorine molecular entity;
mercury coordination entity;
one-carbon compound
thiourea[no description available]medium20one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
1,3-dimethylthiourea[no description available]medium20
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
d-alpha tocopherol[no description available]medium30alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt[no description available]medium10organic molecular entity
arginine[no description available]medium10arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
acetylcysteine[no description available]medium30acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
sodium selenite[no description available]medium20inorganic sodium salt;
selenite salt		nutraceutical
pyrrolidonecarboxylic acid[no description available]medium105-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
2-oxothiazolidine-4-carboxylic acid[no description available]medium10
thiazolidines[no description available]medium10thiazolidine
omega-n-methylarginine[no description available]medium10amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
nitrites[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
sepharose[no description available]medium10
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
cytidine diphosphate choline[no description available]medium10nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
choline[no description available]medium10cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
s-adenosylmethionine[no description available]medium10organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
acid phosphatase[no description available]medium30
phosphamidon[no description available]medium20
1,1-dimethylurea[no description available]medium10
dactinomycin[no description available]medium10actinomycinmutagen
1,7-phenanthroline[no description available]medium10phenanthroline
3-aminobenzamide[no description available]medium10benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
selenium[no description available]medium20chalcogen;
nonmetal atom		micronutrient
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
ebselen[no description available]medium10benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
alloxan[no description available]medium10pyrimidonehyperglycemic agent;
metabolite
tert-butylhydroperoxide[no description available]medium10alkyl hydroperoxideantibacterial agent;
oxidising agent
1-methyl-3-isobutylxanthine[no description available]medium103-isobutyl-1-methylxanthine
thiobarbituric acid[no description available]medium10barbituratesallergen;
reagent
thallium[no description available]medium10boron group element atom
succimer[no description available]medium30dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
bonellin[no description available]medium10
alpha-linolenic acid[no description available]medium10linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
meclofenoxate[no description available]medium10monocarboxylic acid
hematoporphyrin[no description available]medium10
3-mercaptopropionic acid[no description available]medium10mercaptopropanoic acidalgal metabolite
thiorphan[no description available]low00N-acyl-amino acid
tiopronin[no description available]low00N-acyl-amino acid
n-phenylacetylphenylalanine[no description available]low00N-acyl-amino acid
stepronin[no description available]low00N-acyl-amino acid
gusperimus[no description available]low00N-acyl-amino acid
erdosteine[no description available]low00N-acyl-amino acid
st 679[no description available]low00N-acyl-amino acid
flomoxef[no description available]low00N-acyl-amino acid;
organonitrogen heterocyclic antibiotic;
oxacephem		antibacterial drug
n-benzoylalanine, (dl-ala)-isomer[no description available]low00alanine derivative;
N-acyl-amino acid		metabolite
palinavir[no description available]low00N-acyl-amino acid
coronatine[no description available]low00N-acyl-amino acid
racecadotril[no description available]low00N-acyl-amino acid
n-acetyl-s-(2-hydroxyethyl)cysteine[no description available]low00N-acyl-amino acid
n-acetyl-s-(n-methylcarbamoyl)cysteine[no description available]low00N-acyl-amino acid
sr 48692[no description available]low00N-acyl-amino acid
jstx-3[no description available]low00N-acyl-amino acid
argiotoxin-636[no description available]low00N-acyl-amino acid
ilomastat[no description available]low00hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
fr 120480[no description available]low00N-acyl-amino acid
philanthotoxin 343[no description available]low00N-acyl-amino acid
ceronapril[no description available]low00N-acyl-amino acid
succinylproline[no description available]low00N-acyl-amino acid
lacosamide[no description available]low00N-acyl-amino acid
1-Acetamidocyclopentanecarboxylic acid[no description available]low00N-acyl-amino acid
2-acetamido-2-(hydroxymethyl)propanedioic acid diethyl ester[no description available]low00N-acyl-amino acid
benzoylphenylalanine[no description available]low00benzamides;
N-acyl-amino acid
n-acetylproline[no description available]low00N-acyl-amino acid
plasminogen activator inhibitor 2[no description available]low00N-acyl-amino acid
n-heptanoyl-homoserine lactone[no description available]low00N-acyl-amino acid
Spicamycin[no description available]low00N-acyl-amino acid
1-[[(4-chloroanilino)-oxomethyl]amino]-N-[3-(4-morpholinyl)propyl]-1-cyclohexanecarboxamide[no description available]low00N-acyl-amino acid
1-[1-[oxo(1-pyrrolidinyl)methyl]cyclohexyl]-3-(phenylmethyl)urea[no description available]low00N-acyl-amino acid
2-[[[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methyl-3-furanyl]-oxomethyl]amino]acetic acid ethyl ester[no description available]low00N-acyl-amino acid
1-(3-fluorophenyl)-3-[1-[(4-methyl-1-piperazinyl)-oxomethyl]cyclohexyl]urea[no description available]low00N-acyl-amino acid
1-[1-[(4-hydroxy-1-piperidinyl)-oxomethyl]cyclohexyl]-3-(2-methoxyphenyl)urea[no description available]low00N-acyl-amino acid
1-[1-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl(oxo)methyl]cyclohexyl]-3-cyclohexylurea[no description available]low00N-acyl-amino acid
2-acetamido-3,3,3-trifluoro-2-[(6-methylsulfonyl-1,3-benzothiazol-2-yl)amino]propanoic acid methyl ester[no description available]low00N-acyl-amino acid
N-[2-(4-fluoroanilino)-2-oxoethyl]-2-furancarboxamide[no description available]low00N-acyl-amino acid
N-[2-(2,3-dimethylanilino)-2-oxoethyl]-3-(3-methylphenoxy)propanamide[no description available]low00N-acyl-amino acid
Methyl(2-furoylamino)acetic acid[no description available]low00N-acyl-amino acid
N-[3-(4-chlorophenyl)-5-oxo-4-pyrazolidinyl]-3-methylbenzamide[no description available]low00N-acyl-amino acid
N-[4-cyano-5-methyl-2-oxo-3-(trifluoromethyl)-1H-pyrrol-3-yl]cyclopropanecarboxamide[no description available]low00N-acyl-amino acid
2,4-dichloro-N-[2,4,6-trioxo-1-(phenylmethyl)-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzamide[no description available]low00N-acyl-amino acid
N-[1-oxo-1-[[4-(2-pyridinyl)-2-thiazolyl]amino]propan-2-yl]-2-furancarboxamide[no description available]low00N-acyl-amino acid
2-(1-oxopropylamino)acetic acid phenacyl ester[no description available]low00N-acyl-amino acid
N-[2-(3-ethoxypropylamino)-1-(4-methoxyphenyl)-2-oxoethyl]-2-pyrazinecarboxamide[no description available]low00N-acyl-amino acid
2-(2-methoxyphenyl)-1-oxo-N-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-isoquinolinecarboxamide[no description available]low00N-acyl-amino acid
N-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-2-[[1-oxo-2-(1-oxo-2-isoquinolinyl)ethyl]amino]acetamide[no description available]low00N-acyl-amino acid
2-[[2-(3-methyl-1-oxo-2-isoquinolinyl)-1-oxoethyl]amino]acetic acid ethyl ester[no description available]low00N-acyl-amino acid
l 735821[no description available]low00N-acyl-amino acid
sr 142948[no description available]low00N-acyl-amino acid
indolylacryloylglycine[no description available]low00N-acyl-amino acid
glycine linoleamide[no description available]low00N-acyl-amino acid
bengamide e[no description available]low00N-acyl-amino acid
rhc 3659[no description available]low00N-acyl-amino acid
N-[2-[2-(dibutylamino)ethylamino]-2-oxoethyl]-2-thiophenecarboxamide[no description available]low00N-acyl-amino acid
n-hexanoyl-l-homoserine lactone[no description available]low00N-acyl-amino acid
n-dodecanoyl-dl-homoserine lactone[no description available]low00N-acyl-amino acid
spergualin[no description available]low00N-acyl-amino acid
3-methylbutanoic acid [(2R,3S,6S,7R)-3-[[(3-formamido-2-hydroxyphenyl)-oxomethyl]amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] ester[no description available]low00N-acyl-amino acid
N-[5-Ethyl-1-(2-morpholin-4-ylethyl)-2-oxo-3H-indol-3-yl]acetamide;hydron;chloride[no description available]low00N-acyl-amino acidanticoronaviral agent
N-[5-Bromo-1-(2-morpholin-4-ylethyl)-2-oxo-3H-indol-3-yl]acetamide;hydron;chloride[no description available]low00N-acyl-amino acidanticoronaviral agent
N-[5-Fluoro-1-(2-morpholin-4-ylethyl)-2-oxo-3H-indol-3-yl]acetamide;hydron;chloride[no description available]low00N-acyl-amino acidanticoronaviral agent
2-[[[4-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-5-yl]-oxomethyl]amino]acetic acid tert-butyl ester[no description available]low00N-acyl-amino acid;
tert-butyl ester
3-(2,4-dimethoxyphenyl)-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-oxo-1-phthalazinecarboxamide[no description available]low00N-acyl-amino acid
folic acid[no description available]low00folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
raltitrexed[no description available]low00N-acyl-amino acid
ConditionIndicatedRelationship StrengthStudiesTrials
Abnormalities, Drug-Induced0low10
Acute Liver Injury, Drug-Induced0low10
Adult Neuronal Ceroid Lipofuscinosis0low10
Aging0low10
Agranulocytosis0low10
Allergy, Drug0low10
Alloxan Diabetes0low40
Amaurotic Idiocy, Adult Type0low10
Anemia, Fanconi0low10
Autoimmune Diabetes0low20
Batten Disease0low10
Batten-Mayou Disease0low10
Batten-Spielmeyer-Vogt Disease0low10
Benign Neoplasms0low20
Bile Duct Obstruction, Intrahepatic0low10
Biliary Stasis, Intrahepatic0low10
Bleb0low10
Blister0low10
Brain Diseases0low10
Brain Disorders0low10
Bulla0low10
Bullae0low10
Bullous Lesion0low10
Cancer0low20
Canine Diseases0low10
Carbon Tetrachloride Poisoning0low20
Carcinoma0low10
Carcinoma, Anaplastic0low10
Carcinoma, Spindle-Cell0low10
Carcinoma, Undifferentiated0low10
Carcinomatosis0low10
CCl4 Poisoning0low20
Central Nervous System Disorders, Intracranial0low10
Central Nervous System Intracranial Disorders0low10
Ceroid Lipofuscinosis, Neuronal 3, Juvenile0low10
Ceroid Lipofuscinosis, Neuronal 40low10
Ceroid Lipofuscinosis, Neuronal, 30low10
Ceroid Lipofuscinosis, Neuronal, 4A, Autosomal Recessive0low10
Ceroid Lipofuscinosis, Neuronal, 4B, Autosomal Dominant0low10
Ceroid Lipofuscinosis, Neuronal, Parry Type0low10
Ceroid Storage Disease0low10
Ceroid-Lipofuscinosis, Neuronal0low10
Chemical and Drug Induced Liver Injury0low10
Chemically-Induced Liver Toxicity0low10
Cholestasis, Intrahepatic0low10
Chronic Disease0medium11
Chronic Illness0medium11
Chronically Ill0medium11
CLN3-Related Neuronal Ceroid-Lipofuscinosis0low10
CLN4A0low10
CLN4B0low10
CNS Disorders, Intracranial0low10
Communicable Diseases0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Cornea Injuries0low10
Corneal Abrasions0low10
Corneal Damage0low10
Corneal Injuries0low10
Corneal Scar0low10
Corneal Trauma0low10
Dermatitis0low10
Dermatitis Medicamentosa0low10
Dermatitis, Adverse Drug Reaction0low10
Dermatitis, Eczematous0low10
Diabetes Mellitus, Brittle0low20
Diabetes Mellitus, Experimental0low40
Diabetes Mellitus, Insulin-Dependent0low20
Diabetes Mellitus, Insulin-Dependent, 10low20
Diabetes Mellitus, Juvenile-Onset0low20
Diabetes Mellitus, Ketosis-Prone0low20
Diabetes Mellitus, Sudden-Onset0low20
Diabetes Mellitus, Type 10low20
Diabetes Mellitus, Type I0low20
Diabetes, Autoimmune0low20
Disease Models, Animal0low20
Dog Diseases0low10
Drug Allergy0low10
Drug Eruptions0low10
Drug Hypersensitivity0low10
Drug-Induced Abnormalities0low10
Drug-Induced Acute Liver Injury0low10
Drug-Induced Liver Disease0low10
Drug-Induced Liver Injury0low10
Eczema0low10
Encephalitis, Polio0low10
Encephalon Diseases0low10
Encephalopathy0low10
Epidemic Acute Poliomyelitis0low10
Epithelial Neoplasms, Malignant0low10
Epithelial Tumors, Malignant0low10
Epithelioma0low10
Erythema0low10
Experimental Diabetes Mellitus0low40
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Female Genital Neoplasms0low10
Fever0low10
Fever, Zika0low10
Genital Neoplasms, Female0low10
Granulocytopenia0low10
Gynecologic Neoplasms0low10
Hepatitis0medium51
Hepatitis A0low30
Hepatitis, Drug-Induced0low10
Hepatitis, Infectious0low30
Hepatitis, Toxic0low10
Hepatitis, Viral, Human0medium11
Hyperlipemia0low10
Hyperlipidemia0low10
Hyperlipidemias0low10
Hypermelanosis0low10
Hyperpigmentation0low10
Hypersensitivity, Drug0low10
IDDM0low20
Infantile Neuronal Ceroid Lipofuscinosis0low10
Infantile Paralysis0low10
Infectious Diseases0low10
Infectious Hepatitis0low30
Insulin-Dependent Diabetes Mellitus 10low20
Intracranial Central Nervous System Disorders0low10
Intracranial CNS Disorders0low10
Intrahepatic Cholestasis0low10
Itching0low20
Jansky-Bielschowsky Disease0low10
Juvenile Batten Disease0low10
Juvenile Cerebroretinal Degeneration0low10
Juvenile Neuronal Ceroid Lipofuscinosis0low10
Juvenile-Onset Diabetes0low20
Kuf's Disease0low10
Kufs Disease0low10
Kufs Disease Autosomal Recessive0low10
Kufs Disease, Autosomal Dominant0low10
Kufs Disease, Autosomal Recessive0low10
Kufs Type Neuronal Ceroid Lipofuscinosis0low10
Late-Infantile Neuronal Ceroid Lipofuscinosis0low10
Lichen Simplex Chronicus0low10
Lipemia0low10
Lipidemia0low10
Lipofuscin Storage Disease0low10
Lipofuscinosis, Neuronal Ceroid0low10
Liver Diseases0low10
Liver Dysfunction0low10
Liver Injury, Drug-Induced0low10
Liver Injury, Drug-Induced, Acute0low10
Maculopapular Drug Eruption0low10
Maculopapular Exanthem0low10
Malignancy0low20
Malignant Epithelial Neoplasms0low10
Malignant Neoplasms0low20
Mercury Poisoning0low10
Morbilliform Drug Reaction0low10
Morbilliform Exanthem0low10
Neoplasia0low20
Neoplasm0low20
Neoplasms0low20
Neoplasms, Benign0low20
Neoplasms, Female Genital0low10
Neoplasms, Gynecologic0low10
Neoplasms, Malignant Epithelial0low10
Neurodermatitis0low10
Neurodermatitis, Circumscribed0low10
Neurodermatitis, Localized0low10
Neuronal Ceroid Lipofuscinosis0low10
Neuronal Ceroid Lipofuscinosis Juvenile Type0low10
Neuronal Ceroid Lipofuscinosis, Adult0low10
Neuronal Ceroid Lipofuscinosis, Adult Type0low10
Neuronal Ceroid Lipofuscinosis, Infantile0low10
Neuronal Ceroid Lipofuscinosis, Juvenile0low10
Neuronal Ceroid Lipofuscinosis, Late Infantile0low10
Neuronal Ceroid Lipofuscinosis, Late-Infantile0low10
Neuronal Ceroid-Lipofuscinoses0low10
Neuronal Ceroid-Lipofuscinosis0low10
Odontalgia0low10
Palmoplantaris Pustulosis0low10
Poisoning, Carbon Tetrachloride0low20
Poisoning, CCl40low20
Poisoning, Mercury0low10
Polio0low10
Polio Encephalitis0low10
Poliomyelitis0low10
Poliomyelitis Infection0low10
Poliomyelitis, Acute0low10
Poliomyelitis, Nonpoliovirus0low10
Poliomyelitis, Preparalytic0low10
Pruritis0low20
Pruritus0low20
Psoriasis0low10
Pustular Psoriasis of Palms and Soles0low10
Pustulosis of Palms and Soles0low10
Pustulosis Palmaris et Plantaris0low10
Pyrexia0low10
Santavuori-Haltia Disease0low10
Serum Sickness0low10
Spielmeyer-Sjogren Disease0low10
Spielmeyer-Vogt Disease0low10
Streptozocin Diabetes0low40
Streptozotocin Diabetes0low40
Toothache0low10
Toxic Hepatitis0low10
Tumors0low20
Type 1 Diabetes0low20
Type 1 Diabetes Mellitus0low20
Vesication0low10
Viral Hepatitis, Human0medium11
Vogt Spielmeyer Disease0low10
Vogt-Spielmeyer Disease0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (1)

ArticleYear
Phosphamidon neurotoxicity: protection by acetylhomocysteine thiolactone.
Neuroreport, Volume: 2, Issue: 1		1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]